3PC-011 Effectiveness of 3% topical imiquimod in off-label use for oral florida papillomatosis: a case report

• Published in: European journal of hospital pharmacy. Science and practice Vol. 26; no. Suppl 1; p. A42
• Main Authors: Rendón de Lope, L, Ruiz Huertas, P, Donoso-Rengifo, C, Murillo Izquierdo, M, Castillo Martin, C, Cordero Ramos, J, Alvarado Fernandez, MD, Fernandez Gonzalez, M, Moya Martin, ML
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01-03-2019
• Subjects: Antiviral drugs; Biopsy; Case reports
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2019-eahpconf.92

BackgroundImiquimod is an immunomodulator, with antitumour activity, indicated for the treatment of genital and perianal warts produced by the human papilloma virus (HPV), actinic keratosis and basal cell carcinoma.PurposeDescription of a clinical case of papillomatosis (POF) treated with topical imiquimod at 3% in a patient with numerous recurrences after failure of surgical treatment: a 74 years’-old woman, diagnosed with POF in 2008, intervened in 2010, presenting numerous recurrences due to non-responses to treatment. In 2011, verrucous carcinoma and proliferative verrucous hyperplasia were detected in biopsy, and it was again intervened for extirpation in 2017 and 2018. After an exhaustive literature review, it was decided to start treatment with 3% topical imiquimodMaterial and methodsThe elaboration was carried out using an oral adhesive excipient to prolong the permanence of the drug in oral mucosa and reduce the adverse effects on healthy skin areas, and also liquid petrolatum to increase the interposition between the drug and the excipient. A whitish paste, easy to apply, was obtained. The posology was one application at night, 3 days per week, resting at weekends. Each application assumes a dose of approximately 0.01 g of imiquimod (340 mg of preparation). Hyaluronic acid gel was added in order to reduce the adverse effects of imiquimod on healthy perilesional mucosa.ResultsDuring the first two weeks of treatment, the patient presented a decrease in the volume of the lesions. After 8 weeks of treatment, the patient presented good tolerance, without adverse reactions or complications, and reduction of lesions. After 16 weeks of treatment, the papillomatous lesions of the floor of the mouth and lingual tip had disappeared, and a small lesion remained in the lower lip. Currently the patient does not present apparent symptoms, waiting for the result of the biopsy.ConclusionThe clinical evolution of the patient suggests that the oral application of imiquimod 3% is safe and well tolerated, being effective in the treatment of POF and thus avoiding repeated surgical interventions. In addition, its preparation with oral adhesive excipient and its nocturnal application favour the permanence of the drug in the affected area, ensuring the pharmacological effect.Reference and/or acknowledgementsBanerjee S, Kaunelis D. Imiquimod for the treatment of actinickeratosis: a review of clinical effectiveness and cost-effectiveness.No conflict of interest.